Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

110.00
+1.080.99%
Post-market: 110.000.00000.00%19:30 EDT
Volume:523.14K
Turnover:57.65M
Market Cap:7.57B
PE:-35.29
High:112.59
Open:109.38
Low:106.58
Close:108.92
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:1.08
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:73.54
PE(LYR):-35.37

Loading ...

Analysts Conflicted on These Healthcare Names: Rhythm Pharmaceuticals (RYTM) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Apr 17

Rhythm Pharmaceuticals updates financial calendar with first-quarter results call

Reuters
·
Apr 09

Why Rhythm Pharmaceuticals (RYTM) Is Up 12.6% After EU IMCIVREE Expansion Boost and Board Refresh – And What's Next

Simply Wall St.
·
Apr 08

Rhythm Pharmaceuticals appoints Popovits to board of directors

TIPRANKS
·
Apr 06

A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach

Simply Wall St.
·
Apr 04

Rhythm Pharmaceuticals appoints Kim Popovits to board as Ed Mathers exits

Reuters
·
Apr 03

Rhythm Pharmaceuticals Announces Changes to Board of Directors

THOMSON REUTERS
·
Apr 03

Rhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity

Simply Wall St.
·
Mar 30

Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Mar 27

Rhythm Pharmaceuticals rises; CHMP recommends expanding IMCIVREE EU authorization for acquired hypothalamic obesity, EC decision due Q2 2026

Reuters
·
Mar 26

Rhythm Pharmaceuticals Inc: European Commission Decision Anticipated in Q2 of 2026

THOMSON REUTERS
·
Mar 26

Rhythm Pharmaceuticals Receives Positive Chmp Opinion for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients With Acquired Hypothalamic Obesity Due to Hypothalamic Injury or Impairment

THOMSON REUTERS
·
Mar 26

Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 23

Rhythm Pharmaceuticals price target raised to $105 from $100 at H.C. Wainwright

TIPRANKS
·
Mar 23

Assessing Rhythm Pharmaceuticals (RYTM) Valuation After FDA Approval Expands IMCIVREE’s Obesity Indication

Simply Wall St.
·
Mar 23

Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $105 From $100

THOMSON REUTERS
·
Mar 23

Rhythm Pharmaceuticals picks PANTHERx Rare as exclusive US pharmacy partner for IMCIVREE expanded indication

Reuters
·
Mar 21

Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA

TIPRANKS
·
Mar 20

Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN)

TIPRANKS
·
Mar 20

BUZZ-U.S. STOCKS ON THE MOVE-Unilever, Janus, Arm Holdings

Reuters
·
Mar 20